REHOVOT, Israel, Dec. 1, 2020 /PRNewswire/
-- CollPlant (NASDAQ: CLGN), a regenerative and
aesthetics medicine company, today announced financial results for
the third quarter ended September 30,
2020 and provided an update on the Company's business
developments. Certain metrics, including those expressed on an
adjusted basis, are non-GAAP measures. See "Use of Non-GAAP
Measures" below.
CollPlant reported revenues of $4.1
million for the third quarter of 2020, a 511% increase from
the $679,000 recorded in the third
quarter of 2019. The Company ended the third quarter of 2020 with
$5.0 million in cash and cash
equivalents. Comprehensive income for the third quarter of 2020 was
$703,000 on a GAAP basis, or adjusted
comprehensive income of $1.1 million,
on a non-GAAP basis.
"We are very pleased with the progress of our collaboration with
United Therapeutics which started with lungs and is now expanding
to cover kidneys, a second lifesaving organ. The $3 million payment for the option exercise which
contributed to our profitability in the third quarter of 2020 is
part of a larger agreement signed in October
2018 that includes upfront and milestone payments plus
royalties," stated Yehiel Tal,
CollPlant's Chief Executive Officer.
"We continue to advance our medical aesthetics line with
next-generation, regenerative, photocurable dermal fillers which we
believe will yield skin rejuvenation inclusive of the ability to
inject into deep wrinkles, as well as other key attributes. During
the third quarter of 2020 we shared updates on our photocurable
dermal fillers and on our breast implant product pipeline, at the
exclusive Science of Aging Virtual Symposium 2020."
"Furthermore, we are moving forward with a development
program of an antiviral agent for the potential treatment of
COVID-19. We got promising preclinical data showing our platform
technology significantly inhibited avian coronavirus infectivity.
The data indicated our formulation that is comprised of rhCollagen
imbedded with silver nanoparticles (AgNP), targets viral load in
COVID-19 patients, thereby potentially assisting the body's immune
system to combat viral infection, reduce transmission rates between
people, and ultimately reduce the percentage of patients who need
to be treated in critical care settings," Mr. Tal concluded.
Financial Results
Third Quarter 2020 Financial Results on U.S. GAAP basis
("GAAP")
Revenues for the three months ended September 30, 2020 increased by 511% to
$4.1 million, compared to
$679,000 in the third quarter of
2019. Revenues were derived mainly from sales of CollPlant's BioInk
for the development of 3D bioprinting of human organs, the exercise
of an option by United Therapeutics for licensing CollPlant
technology to print kidneys, and from sales of rhCollagen for
medical aesthetics product development.
Cost of revenue was $1.4 million
in the three months ended September 30,
2020, an increase of 123% compared to $645,000 in the same period in 2019. The increase
is primarily related to royalties payments to the Israel Innovation
Authority on revenue from licensing CollPlant's technology to
United Therapeutics for printing of kidneys.
The Company's gross profit for the three months ended
September 30, 2020 increased by
$2.7 million to $2.7 million, or 65% of revenues, in the third
quarter of 2020, compared to $34,000,
or 5% of revenues in the third quarter of 2019.
Total operating expenses for the three months ended September 30, 2020 were $2.0 million, an increase of 11% compared to
$1.8 million in the third quarter of
2019. The increase is primarily related to share-based compensation
expenses for options grant.
Operating profit for the three months ended September 30, 2020 was $734,000, compared to an operating loss of
$1.7 million in the third quarter of
2019.
Financial expense, net for the three months ended September 30, 2020 was $31,000 compared to $1.4
million in the third quarter of 2019. Financial expense in
the three months ended September 30,
2020 and September 30, 2019
mainly derived from non-cash exchange differences of operating
lease liabilities under ASC 842, and re-evaluation of financial
instruments.
Comprehensive income for the third quarter of 2020 was
$703,000, or $0.10 per share, compared to a comprehensive loss
of $3.2 million, or $0.68 per share, for the third quarter of
2019.
Cash used in operating activities during the nine months ended
September 30, 2020 was $2.9 million compared to $4.1 million in the nine months ended
September 30, 2019. As of
September 30, 2020, cash and cash
equivalents totaled $5.0 million.
Cash used in investing activities during the nine months ended
September 30, 2020 was $378,000 compared to $1.2
million in the nine months ended September 30, 2019. The decrease is mainly
attributable to costs incurred in the establishment in 2019 of
CollPlant's new HQ and R&D center in Rehovot, Israel.
Cash provided by financing activities during the nine months
ended September 30, 2020 was
$4.5 million, of
which $4.4 million are attributable to proceeds from
issuance of shares in a private placement in February 2020. Cash provided in the nine months
ended September 30, 2019 by financing
activities amounted to $5.4 million,
and are attributed to proceeds from funding in September 2019.
Third Quarter 2020 Financial Results on Non-U.S. GAAP Basis
("non-GAAP")
On a non-GAAP basis, the operating expenses for the third
quarter of 2020 were $1.6 million, a
decrease of $106,000 compared to
$1.7 million for the third quarter of
2019.
Comprehensive income for the third quarter of 2020 was
$1.1 million, or $0.16 per share, compared to comprehensive loss
of $1.8 million, or $0.38 per share, for the third quarter of
2019.
Non-GAAP measures exclude certain non-cash expenses. The table
on page 10 includes a reconciliation of the Company's GAAP results
to non-GAAP results. The reconciliation reflects non-cash expenses
in the amount of $397,000 with
respect to (i) change in fair value of financial instruments, (ii)
share-based compensation to employees, directors and consultants
and (iii) change of operating lease accounts, including related
financial expenses.
Use of Non-GAAP Measures
This press release contains certain non-GAAP financial measures
for operating costs and expenses, operating loss, comprehensive
loss and basic and diluted comprehensive loss per share that
exclude the effects of non-cash expense for fair market value
attributed to change in fair value of financial instruments,
share-based compensation to employees, directors and consultants,
and change in operating lease accounts. Management believes that
these non-GAAP financial measures provide meaningful supplemental
information regarding the Company's performance that enhances
management's and investors' ability to evaluate the Company's
operating costs, comprehensive loss and loss per share, and to
compare them to historical Company results.
The presentation of this non-GAAP financial information is not
intended to be considered in isolation or as a substitute for the
financial information prepared and presented in accordance with
GAAP. Management uses both GAAP and non-GAAP measures when
operating and evaluating the Company's business internally and
therefore decided to make these non-GAAP adjustments available to
investors. The non-GAAP financial measures used by the Company in
this press release may be different from the measures used by other
companies.
For more information on the non-GAAP financial measures, please
see the "Reconciliation of GAAP to Non-GAAP Financial Measures"
table on page 10 in this press release. This accompanying table on
page 10 has more details on the GAAP financial measures that are
most directly comparable to non-GAAP financial measures and the
related reconciliations between these financial measures.
The Company's consolidated financial results as of, and for the
nine months ended, September 30, 2020
are presented in accordance with generally accepted accounting
principles in the United States of
America ("U.S. GAAP").
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. Our products are based on our rhCollagen (recombinant
human collagen) that is produced with CollPlant's proprietary plant
based genetic engineering technology.
Our products address indications for the diverse fields of
tissue repair, aesthetics and organ manufacturing, and, we believe,
are ushering in a new era in regenerative and aesthetic
medicine.
Our flagship rhCollagen BioInk product line is ideal for 3D
bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
|
(U.S. dollars in
thousands, except share and per share data)
|
(Unaudited)
|
|
|
|
Nine months
ended
September 30
|
|
|
Three months
ended
September 30
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
|
U.S. dollars in
thousands, except per share data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from product
sales
|
|
$
|
1,669
|
|
|
$
|
1,589
|
|
|
$
|
441
|
|
|
$
|
541
|
|
Revenue from
Licensing
|
|
|
3,600
|
|
|
|
-
|
|
|
|
3,600
|
|
|
|
-
|
|
Revenue from
service
|
|
|
311
|
|
|
|
290
|
|
|
|
107
|
|
|
|
138
|
|
Total
Revenue
|
|
|
5,580
|
|
|
|
1,879
|
|
|
|
4,148
|
|
|
|
679
|
|
Cost of
Revenue
|
|
|
2,664
|
|
|
|
1,528
|
|
|
|
1,441
|
|
|
|
645
|
|
Gross
Profit
|
|
|
2,916
|
|
|
|
351
|
|
|
|
2,707
|
|
|
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development, net
|
|
|
2,733
|
|
|
|
2,934
|
|
|
|
921
|
|
|
|
1,078
|
|
General,
administrative and marketing
|
|
|
3,069
|
|
|
|
2,452
|
|
|
|
1,052
|
|
|
|
703
|
|
Total operating
profit (loss)
|
|
|
(2,886)
|
|
|
|
(5,035)
|
|
|
|
734
|
|
|
|
(1,747)
|
|
Financial
income
|
|
|
17
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Financial
expenses
|
|
|
(8)
|
|
|
|
(1,349)
|
|
|
|
(11)
|
|
|
|
(1,391)
|
|
Exchange
differences
|
|
|
8
|
|
|
|
(281)
|
|
|
|
(20)
|
|
|
|
(39)
|
|
Financial income
(expenses), net
|
|
|
17
|
|
|
|
(1,630)
|
|
|
|
(31)
|
|
|
|
(1,430)
|
|
Profit (loss) for
the period
|
|
$
|
(2,869)
|
|
|
$
|
(6,665)
|
|
|
$
|
703
|
|
|
$
|
(3,177)
|
|
Basic profit
(loss) per ordinary share
|
|
$
|
(0.42)
|
|
|
$
|
(1.43)
|
|
|
$
|
0.10
|
|
|
$
|
(0.68)
|
|
Diluted profit
(loss) per ordinary share
|
|
$
|
(0.42)
|
|
|
$
|
(1.43)
|
|
|
$
|
0.07
|
|
|
$
|
(0.68)
|
|
Weighted average
ordinary shares outstanding
|
|
|
6,861,045
|
|
|
|
4,661,204
|
|
|
|
6,962,831
|
|
|
|
4,661,874
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(U.S. dollars in
thousands)
|
(Unaudited)
|
|
|
|
September
30,
|
|
|
December
31,
|
|
|
|
2020
|
|
|
2019
|
|
Assets
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
5,036
|
|
|
$
|
3,791
|
|
Trade
receivables
|
|
|
891
|
|
|
|
79
|
|
Other accounts
receivable and prepaid expenses
|
|
|
550
|
|
|
|
270
|
|
Restricted
deposit
|
|
|
12
|
|
|
|
12
|
|
Inventory
|
|
|
967
|
|
|
|
888
|
|
Total current
assets
|
|
|
7,456
|
|
|
|
5,040
|
|
Non-current
assets:
|
|
|
|
|
|
|
|
|
Restricted
deposit
|
|
|
169
|
|
|
|
168
|
|
Operating lease
right-of-use assets
|
|
|
2,938
|
|
|
|
3,215
|
|
Property and
equipment, net
|
|
|
2,167
|
|
|
|
2,329
|
|
Intangible
assets
|
|
|
46
|
|
|
|
-
|
|
Total non-current
assets
|
|
|
5,320
|
|
|
|
5,712
|
|
Total
assets
|
|
$
|
12,776
|
|
|
$
|
10,752
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(U.S. dollars in
thousands)
|
(Unaudited)
|
|
|
|
September
30,
|
|
|
December
31,
|
|
|
|
2020
|
|
|
2019
|
|
Liabilities and
shareholders' equity
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
Loan
|
|
$
|
6
|
|
|
$
|
24
|
|
Accounts
payable:
|
|
|
|
|
|
|
|
|
Trade
payables
|
|
|
580
|
|
|
|
833
|
|
Accrued liabilities
and other
|
|
|
1,647
|
|
|
|
1,203
|
|
Operating lease
liabilities
|
|
|
420
|
|
|
|
455
|
|
Deferred
revenues
|
|
|
317
|
|
|
|
942
|
|
Total current
liabilities
|
|
|
2,970
|
|
|
|
3,457
|
|
Non-current
liabilities:
|
|
|
|
|
|
|
|
|
Derivatives
|
|
|
52
|
|
|
|
68
|
|
Operating lease
liabilities
|
|
|
2,879
|
|
|
|
3,139
|
|
Total non-current
liabilities
|
|
|
2,931
|
|
|
|
3,207
|
|
Total
liabilities
|
|
|
5,901
|
|
|
|
6,664
|
|
|
|
|
|
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders'
Equity:
|
|
|
|
|
|
|
|
|
Ordinary shares,
NIS 1.5 par value - authorized: 30,000,000 ordinary
shares as of September 30, 2020 and December 31, 2019;
issued
and outstanding: 6,572,753 and 5,670,829 ordinary
shares as of
September 30, 2020 and December 31, 2019,
respectively
|
|
|
2,759
|
|
|
|
2,368
|
|
Additional paid in
capital and warrants
|
|
|
75,214
|
|
|
|
69,949
|
|
Currency translation
differences
|
|
|
(969)
|
|
|
|
(969)
|
|
Accumulated
deficit
|
|
|
(70,129)
|
|
|
|
(67,260)
|
|
Total
shareholders' equity
|
|
|
6,875
|
|
|
|
4,088
|
|
Total liabilities
and shareholders' equity
|
|
$
|
12,776
|
|
|
$
|
10,752
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(U.S. dollars in
thousands)
|
(Unaudited)
|
|
|
|
Nine months
ended
September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
Net cash used in
operations (see Appendix A)
|
|
$
|
(2,854)
|
|
|
$
|
(4,064)
|
|
Net cash used in
operating activities
|
|
|
(2,854)
|
|
|
|
(4,064)
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
Purchase of property
and equipment
|
|
|
(332)
|
|
|
|
(1,154)
|
|
Purchase of
intangible assets
|
|
|
(46)
|
|
|
|
-
|
|
Net cash used in
investing activities
|
|
|
(378)
|
|
|
|
(1,154)
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from
issuance of shares and convertible loan, net
|
|
|
4,400
|
|
|
|
5,440
|
|
Exercise of options
into shares
|
|
|
89
|
|
|
|
7
|
|
Loan paid
|
|
|
(18)
|
|
|
|
(14)
|
|
Payments made for
equipment on financing terms
|
|
|
-
|
|
|
|
(17)
|
|
Net cash provided by
financing activities
|
|
|
4,471
|
|
|
|
5,416
|
|
Increase in cash
and cash equivalents and restricted deposits
|
|
|
1,239
|
|
|
|
198
|
|
Cash and cash
equivalents and restricted deposits at the beginning of the
period
|
|
|
3,971
|
|
|
|
5,663
|
|
Exchange
differences on cash and cash equivalents and restricted
deposits
|
|
|
7
|
|
|
|
58
|
|
Cash and cash
equivalents and restricted deposits at the end of the
period
|
|
$
|
5,217
|
|
|
$
|
5,919
|
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
APPENDICES TO
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(U.S. dollars in
thousands)
|
(Unaudited)
|
|
|
|
Nine months
ended
September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Appendix to the
statement of cash flows
|
|
|
|
|
|
|
A. Net cash used
in operations:
|
|
|
|
|
|
|
Loss
|
|
$
|
(2,869)
|
|
|
$
|
(6,665)
|
|
Adjustments
for:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
494
|
|
|
|
370
|
|
Share-based
compensation to employees and consultants
|
|
|
1,167
|
|
|
|
647
|
|
Exchange differences
on cash and cash equivalents
|
|
|
(7)
|
|
|
|
(58)
|
|
Financial (income)
expenses related to financial instruments
|
|
|
(16)
|
|
|
|
1,381
|
|
Net change of
operating lease accounts
|
|
|
(18)
|
|
|
|
363
|
|
|
|
|
(1,249)
|
|
|
|
(3,962)
|
|
Changes in operating
asset and liability items:
|
|
|
|
|
|
|
|
|
Decrease (increase)
in trade receivables
|
|
|
(812)
|
|
|
|
289
|
|
Increase in
inventory
|
|
|
(79)
|
|
|
|
(18)
|
|
Decrease (increase)
in other receivables (including long-term receivables)
|
|
|
(280)
|
|
|
|
22
|
|
Increase (decrease)
in trade payables (including long-term payables)
|
|
|
(253)
|
|
|
|
161
|
|
Increase in accrued
liabilities and other payables
|
|
|
444
|
|
|
|
232
|
|
Decrease in deferred
revenues (including long term deferred revenues)
|
|
|
(625)
|
|
|
|
(788)
|
|
|
|
|
(1,605)
|
|
|
|
(102)
|
|
Net cash used in
operations
|
|
$
|
(2,854)
|
|
|
$
|
(4,064)
|
|
Supplemental
disclosures of non-cash investing and financing
activities:
|
|
|
|
|
|
|
|
|
Conversion of
pre-paid warrants to ordinary shares
|
|
|
181
|
|
|
|
-
|
|
Obtaining right of
use assets in exchange for a lease liability
|
|
|
-
|
|
|
|
34
|
|
Classification of
warrants from equity to liabilities, net
|
|
|
-
|
|
|
|
1,804
|
|
CollPlant
Biotechnologies Ltd.
|
Reconciliation of
GAAP to Non-GAAP Financial Measures
|
(U.S. dollars in
thousands, except per share data)
|
(Unaudited)
|
|
|
|
Nine months
ended
September 30
|
|
|
Three months
ended
September 30
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
|
|
USD in
thousands
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP
gross profit
|
|
$
|
2,916
|
|
|
$
|
351
|
|
|
$
|
2,707
|
|
|
$
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating
costs and expenses:
|
|
|
5,802
|
|
|
|
5,386
|
|
|
|
1,973
|
|
|
|
1,781
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change of operating
lease accounts
|
|
|
18
|
|
|
|
(363)
|
|
|
|
(14)
|
|
|
|
(71)
|
|
Share-based
compensation to employees, directors and consultants
|
|
|
(1,167)
|
|
|
|
(647)
|
|
|
|
(373)
|
|
|
|
(18)
|
|
Non-GAAP operating
costs and expenses:
|
|
|
4,653
|
|
|
|
4,376
|
|
|
|
1,586
|
|
|
|
1,692
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating
profit (loss)
|
|
|
(2,886)
|
|
|
|
(5,035)
|
|
|
|
734
|
|
|
|
(1,747)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP operating
Profit (loss)
|
|
|
(1,737)
|
|
|
|
(4,025)
|
|
|
|
1,121
|
|
|
|
(1,658)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Comprehensive
income (loss)
|
|
|
(2,869)
|
|
|
|
(6,665)
|
|
|
|
703
|
|
|
|
(3,177)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value
of financial instruments
|
|
|
16
|
|
|
|
(1,381)
|
|
|
|
(10)
|
|
|
|
(1,321)
|
|
Change of operating
lease accounts
|
|
|
18
|
|
|
|
(363)
|
|
|
|
(14)
|
|
|
|
(71)
|
|
Share-based
compensation to employees, directors and consultants
|
|
|
(1,167)
|
|
|
|
(647)
|
|
|
|
(373)
|
|
|
|
(18)
|
|
Non-GAAP
Comprehensive income (loss)
|
|
$
|
(1,736)
|
|
|
$
|
(4,274)
|
|
|
$
|
1,100
|
|
|
$
|
(1,767)
|
|
GAAP basic profit
(loss) per ordinary share
|
|
$
|
(0.42)
|
|
|
$
|
(1.43)
|
|
|
$
|
0.10
|
|
|
$
|
(0.68)
|
|
Non-GAAP basic profit (loss) per ordinary
share
|
|
$
|
(0.25)
|
|
|
$
|
(0.92)
|
|
|
$
|
0.16
|
|
|
$
|
(0.38)
|
|
GAAP diluted
profit (loss) per ordinary share
|
|
|
(0.42)
|
|
|
$
|
(1.43)
|
|
|
$
|
0.07
|
|
|
$
|
(0.68)
|
|
Non-GAAP diluted profit (loss) per ordinary
share
|
|
|
(0.25)
|
|
|
$
|
(0.92)
|
|
|
$
|
0.11
|
|
|
$
|
(0.38)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-third-quarter-q3-2020-financial-results-and-provides-business-update-301182428.html
SOURCE CollPlant